生物标志物引导的保肾脓毒症集束化治疗可行性评估:脓毒症中限制急性肾损伤进展试验
该多中心随机对照试验在5个大学医院ICU纳入19例无急性肾损伤2/3期或慢性肾病的脓毒症成人患者,随机接受标准治疗(n=8)或基于尿[TIMP2]•[IGFBP7]系列测定的三级保肾脓毒症集束化治疗(n=11)。因COVID-19疫情招募缓慢而提前终止。前两级集束化治疗依从性分别为15/19(81.8%)和19/19(100%),第3级为1/4(25%);干预组严重不良事件4/11(36.4%)多于对照组1/8(12.5%),但均与研究干预无关。72小时内死亡、透析或急性肾损伤进展≥2期的复合终点在对照组为3/8(37.5%),干预组为0/11(0%)。作者认为该策略似乎可行且安全。
要点
- 在脓毒症ICU患者中,基于尿[TIMP2]•[IGFBP7]风险分层的KDIGO保肾集束化治疗前两级依从性达81.8%和100%,第3级仅25%。
- 干预组严重不良事件4/11(36.4%)高于对照组1/8(12.5%),但均与研究干预无关。
- 72小时内死亡、透析或急性肾损伤进展≥2期复合终点:对照组3/8(37.5%) vs 干预组0/11(0%)。
- 试验因COVID-19疫情导致招募缓慢而提前终止,仅纳入19例患者。
- 作者认为该生物标志物引导的保肾集束化治疗在脓毒症患者中似乎可行且安全。
适用人群与场景
- 成人患者,入住ICU,留置导尿管,诊断为脓毒症或脓毒性休克,无急性肾损伤2期或3期,无慢性肾病。
处置流程与药物剂量
- 三级保肾脓毒症集束化治疗基于KDIGO推荐,由系列测量尿[TIMP2]•[IGFBP7]联合生物标志物指导。
研究设计与关键结果
- 研究设计:适应性、多中心、随机临床试验,在5个大学医院开展,因COVID-19疫情相关招募缓慢而终止。
- 样本量:19例患者随机分配至标准治疗组(n=8,42.0%)或干预组(n=11,58.0%)。
- 主要终点为可行性:对前两级保肾集束化治疗的依从性为15/19(81.8%)和19/19(100%),第3级为1/4(25%)。
- 安全性:干预组严重不良事件4/11(36.4%),对照组1/8(12.5%),均与研究干预无关。
- 疗效次要终点:72小时内死亡、透析或急性肾损伤进展≥2期的复合终点,对照组3/8(37.5%),干预组0/11(0%);对照组中2例患者急性肾损伤进展,1例死亡。
证据类型、等级与局限
- 证据类型:适应性、多中心、随机临床试验。
- 局限:试验因COVID-19疫情相关招募缓慢而提前终止;样本量小(19例)。
对床旁实践的改变
- 作者认为,尽管COVID-19疫情阻碍了招募,但实际实施基于KDIGO的保肾脓毒症集束化治疗(由尿[TIMP2]•[IGFBP7]风险分层指导)在脓毒症患者中似乎可行且安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the feasibility, safety, and efficacy of a biomarker-guided implementation of a kidney-sparing sepsis bundle (KSSB) of care in comparison with standard of care (SOC) on clinical outcomes in patients with sepsis.
DESIGN: Adaptive, multicenter, randomized clinical trial.
SETTING: Five University Hospitals in Europe and North America.
PATIENTS: Adult patients, admitted to the ICU with an indwelling urinary catheter and diagnosis of sepsis or septic shock, without acute kidney injury (acute kidney injury) stage 2 or 3 or chronic kidney disease.
INTERVENTIONS: A three-level KSSB based on Kidney Disease: Improving Global Outcomes (KDIGOs) recommendations guided by serial measurements of urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 used as a combined biomarker [TIMP2]•[IGFBP7].
MEASUREMENTS AND MAIN RESULTS: The trial was stopped for low enrollment related to the COVID-19 pandemic. Nineteen patients enrolled in five sites over 12 months were randomized to the SOC (n = 8, 42.0%) or intervention (n = 11, 58.0%). The primary outcome was feasibility, and key secondary outcomes were safety and efficacy. Adherence to protocol in patients assigned to the first two levels of KSSB was 15 of 19 (81.8%) and 19 of 19 (100%) but was 1 of 4 (25%) for level 3 KSSB. Serious adverse events were more frequent in the intervention arm (4/11, 36.4%) than in the control arm (1/8, 12.5%), but none were related to study interventions. The secondary efficacy outcome was a composite of death, dialysis, or progression of greater than or equal to 2 stages of acute kidney injury within 72 hours after enrollment and was reached by 3 of 8 (37.5%) patients in the control arm, and 0 of 11 (0%) patients in the intervention arm. In the control arm, two patients experienced progression of acute kidney injury, and one patient died.
CONCLUSIONS: Although the COVID-19 pandemic impeded recruitment, the actual implementation of a therapeutic strategy that deploys a KDIGO-based KSSB of care guided by risk stratification using urinary [TIMP2]•[IGFBP7] seems feasible and appears to be safe in patients with sepsis.
参考来源
- Gómez H, Zarbock A, Pastores SM, et al. Feasibility Assessment of a Biomarker-Guided Kidney-Sparing Sepsis Bundle: The Limiting Acute Kidney Injury Progression In Sepsis Trial. Crit Care Explor. 2023. PMID: 37614799. doi:10.1097/CCE.0000000000000961
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。